Werner Seeger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8112737/publications.pdf

Version: 2024-02-01

726 papers 49,105 citations

104 h-index 182 g-index

747 all docs

747 docs citations

747 times ranked

38861 citing authors

#	Article	IF	CITATIONS
1	Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. Cardiovascular Research, 2022, 118, 305-315.	3.8	8
2	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure–volume loops. European Heart Journal Cardiovascular Imaging, 2022, 23, 498-507.	1.2	22
3	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. Clinical Research in Cardiology, 2022, 111, 393-405.	3.3	5
4	Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. European Respiratory Journal, 2022, 59, 2002248.	6.7	35
5	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. European Respiratory Journal, 2022, 59, 2101153.	6.7	13
6	Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters. Journal of Heart and Lung Transplantation, 2022, 41, 400-410.	0.6	12
7	Effects of BPA on right ventricular mechanical dysfunction in patients with inoperable CTEPH – A cardiac magnetic resonance study. European Journal of Radiology, 2022, 147, 110111.	2.6	11
8	Differential LysoTracker Uptake Defines Two Populations of Distal Epithelial Cells in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 235.	4.1	6
9	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. International Journal of Molecular Sciences, 2022, 23, 546.	4.1	16
10	Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry. Frontiers in Immunology, 2022, 13, 827719.	4.8	5
11	Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2101698.	6.7	5
12	An essential function for autocrine hedgehog signaling in epithelial proliferation and differentiation in the trachea. Development (Cambridge), 2022, 149, .	2.5	6
13	Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival. Circulation Research, 2022, 130, 760-778.	4. 5	19
14	Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 826369.	2.4	8
15	Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clinical Immunology, 2022, 236, 108961.	3.2	9
16	Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 345-355.	0.6	12
17	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. Circulation, 2022, 145, 916-933.	1.6	21
18	Inhaled Iloprost Improves Right Ventricular Load–Independent Contractility in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 111-114.	5.6	10

#	Article	IF	CITATIONS
19	Effects of preoperative high-oral protein loading on short- and long-term renal outcomes following cardiac surgery: a cohort study. Journal of Translational Medicine, 2022, 20, 204.	4.4	3
20	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Science Translational Medicine, 2022, 14, .	12.4	15
21	Transcriptional Profiling of Insulin-like Growth Factor Signaling Components in Embryonic Lung Development and Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 1973.	4.1	4
22	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132.	2.4	7
23	Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. Cells, 2022, 11, 2121.	4.1	5
24	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
25	Amelioration of elastaseâ€induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. British Journal of Pharmacology, 2021, 178, 152-171.	5.4	17
26	Targeting Jak–Stat Signaling in Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 100-114.	2.9	37
27	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
28	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. ESC Heart Failure, 2021, 8, 183-203.	3.1	82
29	Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L590-L599.	2.9	17
30	Severe organising pneumonia following COVID-19. Thorax, 2021, 76, 201-204.	5.6	68
31	The H2S-generating enzyme 3-mercaptopyruvate sulfurtransferase regulates pulmonary vascular smooth muscle cell migration and proliferation but does not impact normal or aberrant lung development. Nitric Oxide - Biology and Chemistry, 2021, 107, 31-45.	2.7	6
32	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. British Journal of Pharmacology, 2021, 178, 90-107.	5.4	40
33	Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. British Journal of Pharmacology, 2021, 178, 54-71.	5.4	69
34	Genetic Delivery and Gene Therapy in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1179.	4.1	16
35	Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurlPFreg). Journal of Clinical Medicine, 2021, 10, 192.	2.4	7
36	Therapeutic Potential of Regorafenibâ€"A Multikinase Inhibitor in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1502.	4.1	4

3

#	Article	IF	Citations
37	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. Pulmonary Circulation, 2021, 11, 1-7.	1.7	13
38	COVID-19: spot urine rather than bronchoalveolar lavage fluid analysis?. Critical Care, 2021, 25, 162.	5.8	1
39	Utilising biomarkers to predict right heart maladaptive phenotype: a step toward precision medicine. European Respiratory Journal, 2021, 57, 2004506.	6.7	1
40	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine, 2021, 34, 100822.	7.1	22
41	Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1316-1319.	5.6	6
42	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L715-L725.	2.9	21
43	The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L903-L915.	2.9	9
44	Protocol for the generation of murine bronchiolospheres. STAR Protocols, 2021, 2, 100594.	1.2	5
45	Hypercapnia Induces Inositol-Requiring Enzyme 1α–Driven Endoplasmic Reticulum–associated Degradation of the Na,K-ATPase β-Subunit. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 615-629.	2.9	7
46	TRAF2 Is a Novel Ubiquitin E3 Ligase for the Na,K-ATPase \hat{l}^2 -Subunit That Drives Alveolar Epithelial Dysfunction in Hypercapnia. Frontiers in Cell and Developmental Biology, 2021, 9, 689983.	3.7	2
47	PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 226-228.	2.9	9
48	Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. International Journal of Environmental Research and Public Health, 2021, 18, 8280.	2.6	3
49	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Communications Biology, 2021, 4, 1002.	4.4	3
50	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	1.4	6
51	Evidence for Multiple Origins of De Novo Formed Vascular Smooth Muscle Cells in Pulmonary Hypertension: Challenging the Dominant Model of Pre-Existing Smooth Muscle Expansion. International Journal of Environmental Research and Public Health, 2021, 18, 8584.	2.6	0
52	Renal markers for monitoring acute kidney injury transition to chronic kidney disease after COVID-19. Nephrology Dialysis Transplantation, 2021, 36, 2143-2147.	0.7	4
53	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. Cancers, 2021, 13, 4127.	3.7	7
54	Reply to: Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1113.	5.6	0

#	Article	IF	Citations
55	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. European Respiratory Review, 2021, 30, 210059.	7.1	16
56	Adenylate Kinase 4—A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1α Signaling Pathways. International Journal of Molecular Sciences, 2021, 22, 10371.	4.1	11
57	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers, 2021, 13, 208.	3.7	10
58	A comparison of airway pressures for inflation fixation of developing mouse lungs for stereological analyses. Histochemistry and Cell Biology, 2021, 155, 203-214.	1.7	4
59	Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 775039.	2.4	3
60	Evaluation and Prognostic Relevance of Right Ventricular–Arterial Coupling in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 116-119.	5.6	68
61	Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
62	Epithelial cell plasticity defines heterogeneity in lung cancer. Cellular Signalling, 2020, 65, 109463.	3.6	17
63	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 633-642.	1.5	16
64	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H156-H164.	3.2	42
65	Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. European Respiratory Review, 2020, 29, 200134.	7.1	25
66	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5.	1.7	14
67	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	1.7	12
68	IRAG1 Deficient Mice Develop PKG1 \hat{I}^2 Dependent Pulmonary Hypertension. Cells, 2020, 9, 2280.	4.1	7
69	Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients With Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome. Frontiers in Medicine, 2020, 7, 598379.	2.6	13
70	Minoxidil Cannot Be Used To Target Lysyl Hydroxylases during Postnatal Mouse Lung Development: A Cautionary Note. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 478-487.	2.5	2
71	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16.	1.7	9
72	Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg). Journal of Clinical Medicine, 2020, 9, 3763.	2.4	11

#	Article	IF	CITATIONS
73	Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). Journal of Clinical Medicine, 2020, 9, 2499.	2.4	17
74	Impact of litter size on survival, growth and lung alveolarization of newborn mouse pups. Annals of Anatomy, 2020, 232, 151579.	1.9	1
75	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non–Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4414-4425.	0.9	109
76	Impact of SARS oVâ€2 pandemic on pulmonary hypertension outâ€patient clinics in Germany: a multiâ€centre study. Pulmonary Circulation, 2020, 10, 1-3.	1.7	15
77	Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas. Cells, 2020, 9, 1755.	4.1	12
78	Commercially available transfection reagents and negative control siRNA are not inert. Analytical Biochemistry, 2020, 606, 113828.	2.4	4
79	Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. Scientific Reports, 2020, 10, 12864.	3.3	24
80	Pre-transplant renal functional reserve and renal function after lung transplantation. Journal of Heart and Lung Transplantation, 2020, 39, 970-974.	0.6	1
81	Risk assessment in severe pulmonary hypertension due to interstitial lung disease. Journal of Heart and Lung Transplantation, 2020, 39, 1118-1125.	0.6	15
82	Metastasis-Associated Protein 2 Represses NF-κB to Reduce Lung Tumor Growth and Inflammation. Cancer Research, 2020, 80, 4199-4211.	0.9	9
83	Elevated FiO ₂ increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L670-L674.	2.9	11
84	Decreased Thymic Output Contributes to Immune Defects in Septic Patients. Journal of Clinical Medicine, 2020, 9, 2695.	2.4	4
85	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 9099.	4.1	5
86	Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. European Respiratory Journal, 2020, 56, 1901892.	6.7	9
87	Effect of p53 activation on experimental right ventricular hypertrophy. PLoS ONE, 2020, 15, e0234872.	2.5	6
88	Sex Differences in Right Ventricular–Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1042-1046.	5.6	48
89	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
90	Cytochrome P450 epoxygenaseâ€derived 5,6â€epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. Acta Physiologica, 2020, 230, e13521.	3.8	9

#	Article	IF	Citations
91	Reprogramming of tumor-associated macrophages by targeting \hat{l}^2 -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. Science Advances, 2020, 6, eaaz6105.	10.3	110
92	Call it by the correct nameâ€"pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L992-L994.	2.9	17
93	Clinical and Operative Determinants of Acute Kidney Injury after Cardiac Surgery. CardioRenal Medicine, 2020, 10, 340-352.	1.9	10
94	Immunomodulation by an Omega-6 Fatty Acid Reduced Mixed Lipid Emulsion in Murine Acute Respiratory Distress Syndrome. Journal of Clinical Medicine, 2020, 9, 2048.	2.4	4
95	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRÎ ² . American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1445-1457.	5 . 6	45
96	Hypercapnia Impairs Na,K-ATPase Function by Inducing Endoplasmic Reticulum Retention of the \hat{l}^2 -Subunit of the Enzyme in Alveolar Epithelial Cells. International Journal of Molecular Sciences, 2020, 21, 1467.	4.1	13
97	Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model. British Journal of Pharmacology, 2020, 177, 2974-2990.	5.4	3
98	Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 204589402092575.	1.7	5
99	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	1.9	11
100	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. Science Advances, 2020, 6, eaba0694.	10.3	39
101	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. Frontiers in Oncology, 2020, 10, 324.	2.8	76
102	The Lung Vasculature: A Driver or Passenger in Lung Branching Morphogenesis?. Frontiers in Cell and Developmental Biology, 2020, 8, 623868.	3.7	13
103	Identification of a Repair-Supportive Mesenchymal Cell Population during Airway Epithelial Regeneration. Cell Reports, 2020, 33, 108549.	6.4	28
104	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. Journal of Clinical Investigation, 2020, 130, 3560-3575.	8.2	103
105	Hypoxia-inducible factor signaling in pulmonary hypertension. Journal of Clinical Investigation, 2020, 130, 5638-5651.	8.2	104
106	SCRINSHOT enables spatial mapping of cell states in tissue sections with single-cell resolution. PLoS Biology, 2020, 18, e3000675.	5 . 6	42
107	Multilineage murine stem cells generate complex organoids to model distal lung development and disease. EMBO Journal, 2020, 39, e103476.	7.8	44
108	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Global Cardiology Science & Practice, 2020, 2020, e202010.	0.4	1

#	Article	IF	Citations
109	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Global Cardiology Science & Practice, 2020, 2020, e202010.	0.4	1
110	Persistent decrease of renal functional reserve in patients after cardiac surgery-associated acute kidney injury despite clinical recovery. Nephrology Dialysis Transplantation, 2019, 34, 308-317.	0.7	54
111	Susceptibility of microtubuleâ€associated protein 1 light chain 3β (MAP1LC3B/LC3B) knockout mice to lung injury and fibrosis. FASEB Journal, 2019, 33, 12392-12408.	0.5	13
112	Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452.	5.6	4
113	Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF). BMC Pulmonary Medicine, 2019, 19, 130.	2.0	32
114	Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation. Transplant Infectious Disease, 2019, 21, e13138.	1.7	5
115	Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nature Communications, 2019, 10, 2987.	12.8	181
116	Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank. Journal of Clinical Medicine, 2019, 8, 1698.	2.4	20
117	Acute response to rapid iloprost inhalation using the Breelibâ,,¢ nebulizer in pulmonary arterial hypertension: the Breelibâ,,¢ acute study. Pulmonary Circulation, 2019, 9, 1-3.	1.7	4
118	Dopplerâ€Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure. Journal of the American Heart Association, 2019, 8, e013584.	3.7	66
119	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1550-1554.	5.6	8
120	Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2019, 12, e009047.	2.6	222
121	Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. European Respiratory Journal, 2019, 54, 1900342.	6.7	21
122	IRE1 Signaling As a Putative Therapeutic Target in Influenza Virus–induced Pneumonia. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 537-540.	2.9	4
123	Resolvin E1 Improves Mitochondrial Function in Human Alveolar Epithelial Cells during Severe Inflammation. Lipids, 2019, 54, 53-65.	1.7	15
124	Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nature Communications, 2019, 10, 2229.	12.8	53
125	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	12.8	69
126	A RASSF1A-HIF1 \hat{i} ± loop drives Warburg effect in cancer and pulmonary hypertension. Nature Communications, 2019, 10, 2130.	12.8	77

#	Article	IF	CITATIONS
127	A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease. European Respiratory Journal, 2019, 54, 1802435.	6.7	30
128	Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank. Journal of Clinical Medicine, 2019, 8, 643.	2.4	9
129	Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. Journal of Experimental Medicine, 2019, 216, 1377-1395.	8.5	45
130	Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 515-518.	5.6	20
131	Altered proteasome function in right ventricular hypertrophy. Cardiovascular Research, 2019, 116, 406-415.	3.8	9
132	Estimation of absolute number of alveolar epithelial type 2 cells in mouse lungs: a comparison between stereology and flow cytometry. Journal of Microscopy, 2019, 275, 36-50.	1.8	14
133	Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells. Journal of Molecular Medicine, 2019, 97, 973-990.	3.9	31
134	Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respiratory Research, 2019, 20, 47.	3.6	31
135	Mouse genetic background impacts susceptibility to hyperoxiaâ€driven perturbations to lung maturation. Pediatric Pulmonology, 2019, 54, 1060-1077.	2.0	18
136	miRâ€574â€5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGESâ€1 induction. FASEB Journal, 2019, 33, 6933-6947.	0.5	30
137	Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. Cardiovascular Research, 2019, 115, 1217-1227.	3.8	16
138	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest, 2019, 155, 972-981.	0.8	32
139	Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2019, 12, 2155-2164.	5.3	7 5
140	Targeting miRâ€34a/ <i>Pdgfra</i> interactions partially corrects alveologenesis in experimental bronchopulmonary dysplasia. EMBO Molecular Medicine, 2019, 11, .	6.9	38
141	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. European Respiratory Journal, 2019, 53, 1802445.	6.7	25
142	Response by Tello et al to Letter Regarding Article, "Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension†Circulation: Cardiovascular Imaging, 2019, 12, e010059.	2.6	13
143	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine, the, 2019, 7, 227-238.	10.7	122
144	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1407-1420.	5.6	39

#	Article	IF	CITATIONS
145	Multibeat Right Ventricular–Arterial Coupling during a Positive Acute Vasoreactivity Test. American Journal of Respiratory and Critical Care Medicine, 2019, 199, e41-e42.	5.6	8
146	Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. Circulation: Heart Failure, 2019, 12, e005512.	3.9	158
147	Control Interventions Can Impact Alveolarization and the Transcriptome in Developing Mouse Lungs. Anatomical Record, 2019, 302, 346-363.	1.4	6
148	Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal, 2019, 53, 1801914.	6.7	428
149	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 346-356.	2.9	20
150	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology, 2019, 9, 1550.	2.8	26
151	Process Evaluation of a Medical Student–Delivered Smoking Prevention Program for Secondary Schools: Protocol for the Education Against Tobacco Cluster Randomized Trial. JMIR Research Protocols, 2019, 8, e13508.	1.0	2
152	Alterations in Doppler-derived renal venous stasis index during recompensation of right heart failure and fluid overload in a patient with pulmonary hypertension. Reviews in Cardiovascular Medicine, 2019, 20, 263.	1.4	7
153	Resident alveolar macrophages are master regulators of arrested alveolarization in experimental bronchopulmonary dysplasia. Journal of Pathology, 2018, 245, 153-159.	4.5	50
154	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
155	Preoperative Renal Functional Reserve Predicts Risk of Acute Kidney Injury After Cardiac Operation. Annals of Thoracic Surgery, 2018, 105, 1094-1101.	1.3	80
156	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. European Respiratory Journal, 2018, 51, 1701024.	6.7	64
157	Stereological analysis of individual lung lobes during normal and aberrant mouse lung alveolarisation. Journal of Anatomy, 2018, 232, 472-484.	1.5	10
158	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 41.	2.0	46
159	Transmission of microRNA antimiRs to mouse offspring via the maternal–placental–fetal unit. Rna, 2018, 24, 865-879.	3.5	5
160	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 373-385.	5.6	78
161	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Molecular Medicine, 2018, 10, 276-293.	6.9	85
162	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915.	2.5	38

#	Article	IF	CITATIONS
163	Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding― BioMed Research International, 2018, 2018, 1-2.	1.9	0
164	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. Circulation: Cardiovascular Imaging, 2018, 11, e007653.	2.6	10
165	A Face-Aging Smoking Prevention/Cessation Intervention for Nursery School Students in Germany: An Appearance-Focused Interventional Study. International Journal of Environmental Research and Public Health, 2018, 15, 1656.	2.6	7
166	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800564.	6.7	54
167	Nintedanib in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 808-810.	5.6	17
168	More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 816-818.	5.6	63
169	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. BioMed Research International, 2018, 2018, 1-9.	1.9	29
170	Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia. FEBS Journal, 2018, 285, 3056-3076.	4.7	19
171	The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 141.	3.6	199
172	Understanding alveolarization to induce lung regeneration. Respiratory Research, 2018, 19, 148.	3.6	42
173	Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 63-68.	1.7	34
174	MiCEE is a ncRNA-protein complex that mediates epigenetic silencing and nucleolar organization. Nature Genetics, 2018, 50, 990-1001.	21.4	52
175	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 266, 229-235.	1.7	154
176	Resolvin E1 and its precursor 18R-HEPE restore mitochondrial function in inflammation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 1016-1028.	2.4	20
177	Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1720-1723.	8.2	46
178	Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget, 2018, 9, 28976-28988.	1.8	6
179	Facial-Aging Mobile Apps for Smoking Prevention in Secondary Schools in Brazil: Appearance-Focused Interventional Study. JMIR Public Health and Surveillance, 2018, 4, e10234.	2.6	3
180	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. Journal of Medical Internet Research, 2018, 20, e10976.	4.3	19

#	Article	IF	Citations
181	Modelling bronchopulmonary dysplasia in mice: how much oxygen is enough?. DMM Disease Models and Mechanisms, 2017, 10, 185-196.	2.4	84
182	The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. Clinical Respiratory Journal, 2017, 11, 682-690.	1.6	7
183	Caffeine administration modulates TGF- \hat{l}^2 signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. Pediatric Research, 2017, 81, 795-805.	2.3	35
184	Therapeutic and pathological roles of fibroblast growth factors in pulmonary diseases. Developmental Dynamics, 2017, 246, 235-244.	1.8	22
185	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. Journal of Heart and Lung Transplantation, 2017, 36, 957-967.	0.6	221
186	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. Journal of Heart and Lung Transplantation, 2017, 36, 880-889.	0.6	16
187	Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB Journal, 2017, 31, 1916-1928.	0.5	66
188	Amplified canonical transforming growth factor-β signalling <i>via</i> heat shock protein 90 in pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1501941.	6.7	66
189	Ex vivo analysis of the contribution of FGF10 ⁺ cells to airway smooth muscle cell formation during early lung development. Developmental Dynamics, 2017, 246, 531-538.	1.8	24
190	Stereological monitoring of mouse lung alveolarization from the early postnatal period to adulthood. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L882-L895.	2.9	71
191	Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2017, 7, 543-546.	1.7	2
192	The Max Planck Institute for Heart and Lung Research Curiosity-Driven Basic Research to Fight Cardio-Pulmonary Diseases. Circulation Research, 2017, 120, 1386-1389.	4.5	0
193	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. Circulation Research, 2017, 121, 424-438.	4.5	90
194	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 505-513.	1.7	20
195	Identification and Functional Characterization of Hypoxia-Induced Endoplasmic Reticulum Stress Regulating IncRNA (HypERInc) in Pericytes. Circulation Research, 2017, 121, 368-375.	4.5	61
196	In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clinical and Translational Radiation Oncology, 2017, 2, 69-75.	1.7	4
197	Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunology, Immunotherapy, 2017, 66, 799-809.	4.2	33
198	Antihistone Properties of C1 Esterase Inhibitor Protect against Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 186-199.	5.6	39

#	Article	IF	Citations
199	Maintained right ventricular pressure overload induces ventricular–arterial decoupling in mice. Experimental Physiology, 2017, 102, 180-189.	2.0	18
200	TGF-Î ² inhibits alveolar protein transport by promoting shedding, regulated intramembrane proteolysis, and transcriptional downregulation of megalin. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L807-L824.	2.9	11
201	Mesenchymal Stem Cells in Fibrotic Disease. Cell Stem Cell, 2017, 21, 166-177.	11.1	309
202	Lung cancer–associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell–immune cell cross-talk. Science Translational Medicine, 2017, 9, .	12.4	69
203	Perturbations to lysyl oxidase expression broadly influence the transcriptome of lung fibroblasts. Physiological Genomics, 2017, 49, 416-429.	2.3	27
204	Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 589-602.	2.9	14
205	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	2.9	72
206	Tamoxifen dosing for Cre-mediated recombination in experimental bronchopulmonary dysplasia. Transgenic Research, 2017, 26, 165-170.	2.4	8
207	Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. Cell Stem Cell, 2017, 20, 261-273.e3.	11.1	217
208	<i>Fgf10</i> deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. Journal of Pathology, 2017, 241, 91-103.	4.5	54
209	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Clinical Research in Cardiology, 2017, 106, 174-182.	3.3	16
210	T <scp>ranslational</scp> A <scp>dvances in the</scp> F <scp>ield of</scp> P <scp>ulmonary</scp> H <scp>ypertension</scp> .From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 425-437.	5.6	117
211	Use of very old donors for lung transplantation: a dual-centre retrospective analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 1049-1054.	1.4	17
212	Hypercapnia Impairs ENaC Cell Surface Stability by Promoting Phosphorylation, Polyubiquitination and Endocytosis of Î ² -ENaC in a Human Alveolar Epithelial Cell Line. Frontiers in Immunology, 2017, 8, 591.	4.8	29
213	Characteristics and outcomes of a cohort hospitalized for pandemic and seasonal influenza in Germany based on nationwide inpatient data. PLoS ONE, 2017, 12, e0180920.	2.5	17
214	Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 2017, 8, 48436-48452.	1.8	216
215	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. Physiological Reports, 2017, 5, e13146.	1.7	36
216	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	1.8	9

#	Article	IF	Citations
217	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016.	1.8	42
218	A Medical Student-Delivered Smoking Prevention Program, Education Against Tobacco, for Secondary Schools in Germany: Randomized Controlled Trial. Journal of Medical Internet Research, 2017, 19, e199.	4.3	18
219	A Dermatologist's Ammunition in the War Against Smoking: A Photoaging App. Journal of Medical Internet Research, 2017, 19, e326.	4.3	10
220	A Medical Student–Delivered Smoking Prevention Program, Education Against Tobacco, for Secondary Schools in Brazil: Study Protocol for a Randomized Trial. JMIR Research Protocols, 2017, 6, e16.	1.0	14
221	Influenza Virus Infects Epithelial Stem/Progenitor Cells of the Distal Lung: Impact on Fgfr2b-Driven Epithelial Repair. PLoS Pathogens, 2016, 12, e1005544.	4.7	113
222	Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine, 2016, 16, 96.	2.0	12
223	Nonâ€invasive lung cancer diagnosis by detection of <i><scp>GATA</scp>6</i> and <i><scp>NKX</scp>2â€1</i> isoforms in exhaled breath condensate. EMBO Molecular Medicine, 2016, 8, 1380-1389.	6.9	29
224	Photoaging smartphone app promoting poster campaign to reduce smoking prevalence in secondary schools: the Smokerface Randomized Trial: design and baseline characteristics. BMJ Open, 2016, 6, e014288.	1.9	34
225	A Protective Kidney-Lung Approach to Improve Outcomes in Mechanically Ventilated Patients. Blood Purification, 2016, 42, 214-218.	1.8	4
226	Relevance of Angiopoietinâ€2 and Soluble Pâ€Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOM 2 Biomarker Substudy. Pulmonary Circulation, 2016, 6, 516-523.	1.7	7
227	Cancer cell motility is affected through 3D cell culturing and SCF/c-Kit pathway but not by X-irradiation. Radiotherapy and Oncology, 2016, 119, 537-543.	0.6	5
228	The emerging role of epigenetics in pulmonary hypertension. European Respiratory Journal, 2016, 48, 903-917.	6.7	32
229	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1137-1149.	6.7	89
230	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. International Journal of Cardiology, 2016, 223, 821-826.	1.7	20
231	N-3 vs. n-6 fatty acids differentially influence calcium signalling and adhesion of inflammatory activated monocytes: impact of lipid rafts. Inflammation Research, 2016, 65, 881-894.	4.0	13
232	The prognostic impact of thyroid function in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 1427-1434.	0.6	25
233	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. BMC Pulmonary Medicine, 2016, 16, 5.	2.0	12
234	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. International Journal of Cardiology, 2016, 216, 85-91.	1.7	28

#	Article	IF	CITATIONS
235	Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. European Respiratory Review, 2016, 25, 135-140.	7.1	35
236	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 63-68.	3.3	19
237	Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. Journal of Applied Physiology, 2016, 120, 271-281.	2.5	9
238	MAP1LC3B overexpression protects against Hermansky-Pudlak syndrome type-1-induced defective autophagy in vitro. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L519-L531.	2.9	25
239	miR-223–IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovascular Research, 2016, 111, 184-193.	3 . 8	54
240	Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly(lactide- co -glycolide) microparticles. Journal of Controlled Release, 2016, 226, 15-20.	9.9	15
241	Influence of amine-modified poly(vinyl alcohol)s on vibrating-membrane nebulizer performance and lung toxicity. European Journal of Pharmaceutical Sciences, 2016, 86, 34-40.	4.0	6
242	FXYD1 negatively regulates Na+/K+-ATPase activity in lung alveolar epithelial cells. Respiratory Physiology and Neurobiology, 2016, 220, 54-61.	1.6	15
243	Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. European Heart Journal, 2016, 37, 35-44.	2.2	194
244	Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infection. Journal of Clinical Investigation, 2016, 126, 1566-1580.	8.2	99
245	The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension. PLoS ONE, 2016, 11, e0152580.	2.5	8
246	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. PLoS ONE, 2016, 11, e0165982.	2.5	10
247	Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome [#] . Current Pharmaceutical Design, 2016, 22, 1147-1160.	1.9	8
248	Photoaging Mobile Apps in School-Based Tobacco Prevention: The Mirroring Approach. Journal of Medical Internet Research, 2016, 18, e183.	4.3	37
249	Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. Cardiology Journal, 2016, 23, 465-472.	1.2	23
250	Immunomodulation by lipid emulsions in pulmonary inflammation: a randomized controlled trial. Critical Care, 2015, 19, 226.	5 . 8	35
251	Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 83.	3.6	89
252	Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. Respiratory Research, 2015, 16, 127.	3.6	32

#	Article	IF	Citations
253	Characterization of lung-delivered in-situ forming controlled release formulations. Journal of Pharmacy and Pharmacology, 2015, 67, 1349-1354.	2.4	8
254	Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension. Frontiers in Pediatrics, 2015, 3, 63.	1.9	14
255	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. PLoS ONE, 2015, 10, e0139073.	2.5	101
256	5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International, 2015, 2015, 1-8.	1.9	62
257	Peritoneal ultrafiltration for refractory fluid overload and ascites due to pulmonary arterial hypertension. Annals of Hepatology, 2015, 14, 929-932.	1.5	2
258	Cardio-Pulmonary-Renal Interactions. Journal of the American College of Cardiology, 2015, 65, 2433-2448.	2.8	157
259	The H ₂ S-generating enzymes cystathionine β-synthase and cystathionine γ-lyase play a role in vascular development during normal lung alveolarization. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L710-L724.	2.9	46
260	Regulation of macroautophagy in amiodaroneâ€induced pulmonary fibrosis. Journal of Pathology: Clinical Research, 2015, 1, 252-263.	3.0	27
261	Characterization of the platelet-derived growth factor receptor-α-positive cell lineage during murine late lung development. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L942-L958.	2.9	68
262	Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 437-447.	5.6	186
263	Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 110-113.	5.6	54
264	Acute Hemodynamic Effects of Nebulized Iloprost via the Iâ€Neb Adaptive Aerosol Delivery System in Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 162-170.	1.7	12
265	Sildenafil versus Nitric Oxide for Acute Vasodilator Testing in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 305-312.	1.7	15
266	Collagen and elastin cross-linking is altered during aberrant late lung development associated with hyperoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1145-L1158.	2.9	59
267	High mobility group protein-mediated transcription requires DNA damage marker Î ³ -H2AX. Cell Research, 2015, 25, 837-850.	12.0	70
268	PPAR- $\hat{l}\pm$ activation reduced LPS-induced inflammation in alveolar epithelial cells. Experimental Lung Research, 2015, 41, 393-403.	1.2	25
269	Systematic aging of degradable nanosuspension ameliorates vibrating-mesh nebulizer performance. Drug Development and Industrial Pharmacy, 2015, 41, 1704-1709.	2.0	2
270	Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. Respiration, 2015, 90, 63-73.	2.6	21

#	Article	IF	CITATIONS
271	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. European Respiratory Journal, 2015, 46, 1084-1094.	6.7	45
272	Customized Vibrating-Membrane Nozzles for Enhanced Fluid Atomization. Aerosol Science and Technology, 2015, 49, iii-viii.	3.1	6
273	Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. BMC Pulmonary Medicine, 2015, 15, 11.	2.0	6
274	Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax, 2015, 70, 636-646.	5 . 6	71
275	Attenuating endogenous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repair. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1014-L1024.	2.9	19
276	Education Against Tobacco (EAT): a quasi-experimental prospective evaluation of a multinational medical-student-delivered smoking prevention programme for secondary schools in Germany. BMJ Open, 2015, 5, e008093.	1.9	26
277	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	6.7	32
278	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax, 2015, 70, 1022-1032.	5.6	106
279	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS ONE, 2015, 10, e0129327.	2.5	29
280	Photoaging Mobile Apps: A Novel Opportunity for Smoking Cessation?. Journal of Medical Internet Research, 2015, 17, e186.	4.3	21
281	Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment. Thrombosis and Haemostasis, 2014, 112, 1288-1303.	3.4	18
282	Transglutaminase 2: a new player in bronchopulmonary dysplasia?. European Respiratory Journal, 2014, 44, 109-121.	6.7	23
283	Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunology, Immunotherapy, 2014, 63, 1297-1306.	4.2	58
284	Carbon ion radiotherapy of human lung cancer attenuates HIFâ€1 signaling and acts with considerably enhanced therapeutic efficiency. FASEB Journal, 2014, 28, 1412-1421.	0.5	41
285	Changing the Mindset in Life Sciences Toward Translation: A Consensus. Science Translational Medicine, 2014, 6, 264cm12.	12.4	42
286	Systemic hydrogen sulfide administration partially restores normal alveolarization in an experimental animal model of bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L684-L697.	2,9	49
287	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2014, 4, 128-136.	1.7	36
288	Education Against Tobacco (EAT): a quasi-experimental prospective evaluation of a programme for preventing smoking in secondary schools delivered by medical students: a study protocol. BMJ Open, 2014, 4, e004909-e004909.	1.9	18

#	Article	IF	Citations
289	Inhaled Granulocyte/Macrophage Colony–Stimulating Factor as Treatment of Pneumonia-associated Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 609-611.	5.6	70
290	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smoke–induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
291	Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone-Induced Lung Fibrosis. Toxicological Sciences, 2014, 142, 285-297.	3.1	40
292	Lysyl Oxidases Play a Causal Role in Vascular Remodeling in Clinical and Experimental Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1446-1458.	2.4	97
293	Nebulization of Active Pharmaceutical Ingredients with the eFlow®rapid: Impact of Formulation Variables on Aerodynamic Characteristics. Journal of Pharmaceutical Sciences, 2014, 103, 2585-2589.	3.3	12
294	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L986-L995.	2.9	31
295	Hmga2is required for canonical WNT signaling during lung development. BMC Biology, 2014, 12, 21.	3.8	55
296	Arterial hypertension in a murine model of sleep apnea. Journal of Hypertension, 2014, 32, 300-305.	0.5	47
297	The Prognostic Significance of Inspiratory Capacity in Pulmonary Arterial Hypertension. Respiration, 2014, 88, 24-30.	2.6	16
298	TGF- \hat{l}^2 directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E374-83.	7.1	129
299	Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth. Journal of Biological Chemistry, 2014, 289, 26804-26816.	3.4	9
300	Controlling the droplet size of formulations nebulized by vibrating-membrane technology. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 524-529.	4.3	20
301	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. Circulation, 2014, 129, 1510-1523.	1.6	23
302	<i>Fgf10</i> -positive cells represent a progenitor cell population during lung development and postnatally. Development (Cambridge), 2014, 141, 296-306.	2.5	136
303	Phenotypical and ultrastructural features of Oct4â€positive cells in the adult mouse lung. Journal of Cellular and Molecular Medicine, 2014, 18, 1321-1333.	3.6	39
304	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nature Medicine, 2014, 20, 1289-1300.	30.7	233
305	Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: Role of surfactant protein B and C. Acta Biomaterialia, 2014, 10, 4678-4684.	8.3	25
306	Senescence-Associated Secretory Phenotype and Its Possible Role in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 323-333.	2.9	103

#	Article	IF	Citations
307	New metrics for translational research. Lancet Respiratory Medicine, the, 2014, 2, e13-e14.	10.7	4
308	Impact of Short―and Medium hain Fatty Acids on Mitochondrial Function in Severe Inflammation. Journal of Parenteral and Enteral Nutrition, 2014, 38, 587-594.	2.6	38
309	Deregulation of the lysyl hydroxylase matrix cross-linking system in experimental and clinical bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L246-L259.	2.9	43
310	On the correlation of output rate and aerodynamic characteristics in vibrating-mesh-based aqueous aerosol delivery. International Journal of Pharmaceutics, 2014, 461, 34-37.	5. 2	24
311	<i>miR-142-3p</i> balances proliferation and differentiation of mesenchymal cells during lung development. Development (Cambridge), 2014, 141, 1272-1281.	2.5	68
312	Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 474-481.	2.6	57
313	Boosting the aerodynamic properties of vibrating-mesh nebulized polymeric nanosuspensions. International Journal of Pharmaceutics, 2014, 459, 23-29.	5.2	19
314	Glucocorticoids Recruit Tgfbr3 and Smad1 to Shift Transforming Growth Factor- \hat{l}^2 Signaling from the Tgfbr1/Smad2/3 Axis to the Acvrl1/Smad1 Axis in Lung Fibroblasts. Journal of Biological Chemistry, 2014, 289, 3262-3275.	3.4	52
315	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	5.6	75
316	MicroRNA-124 Controls the Proliferative, Migratory, and Inflammatory Phenotype of Pulmonary Vascular Fibroblasts. Circulation Research, 2014, 114, 67-78.	4.5	178
317	Immunomodulation by fish-oil containing lipid emulsions in murine acute respiratory distress syndrome. Critical Care, 2014, 18, R85.	5.8	26
318	Polymer Nanoparticle-Based Controlled Pulmonary Drug Delivery. Methods in Molecular Biology, 2014, 1141, 133-145.	0.9	7
319	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 358-367.	2.9	66
320	Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 106-114.	4.3	33
321	Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunology, Immunotherapy, 2013, 62, 309-320.	4.2	45
322	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	2.8	541
323	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637.	1.7	35
324	Efficient gene delivery to primary alveolar epithelial cells by nucleofection. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L786-L794.	2.9	13

#	Article	IF	CITATIONS
325	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72.	2.8	596
326	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	2.8	518
327	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. Antioxidants and Redox Signaling, 2013, 19, 2213-2231.	5.4	62
328	Following the Concentration of Polymeric Nanoparticles During Nebulization. Pharmaceutical Research, 2013, 30, 16-24.	3. 5	26
329	Cofilin, a hypoxiaâ€regulated protein in murine lungs identified by 2 <scp>DE</scp> : Role of the cytoskeletal protein cofilin in pulmonary hypertension. Proteomics, 2013, 13, 75-88.	2.2	16
330	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. Journal of Proteomics, 2013, 85, 109-128.	2.4	64
331	Sleep apnea in precapillary pulmonary hypertension. Sleep Medicine, 2013, 14, 247-251.	1.6	7 5
332	Macrophage-expressed IFN-β Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia. PLoS Pathogens, 2013, 9, e1003188.	4.7	195
333	Effects of Dimethylarginine Dimethylaminohydrolase–1 Overexpression on the Response of the Pulmonary Vasculature to Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 491-500.	2.9	17
334	Quantitative Proteome Analysis of Alveolar Type-II Cells Reveals a Connection of Integrin Receptor Subunits Beta 2/6 and WNT Signaling. Journal of Proteome Research, 2013, 12, 5598-5608.	3.7	10
335	Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459.	5.6	77
336	Shortâ€Term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Longâ€Term Survival in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 523-532.	1.7	20
337	Obstructive Sleep Apnea, Oxidative Stress and Cardiovascular Disease: Lessons from Animal Studies. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-7.	4.0	89
338	Pivotal Role of Matrix Metalloproteinase 13 in Extracellular Matrix Turnover in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2013, 8, e73279.	2.5	77
339	Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis. PLoS ONE, 2013, 8, e79798.	2.5	75
340	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. Histology and Histopathology, 2013, 28, 691-9.	0.7	15
341	Influence of Early Growth Response 1 (Egr1) and Tenascin C (Tnc) on compensatory lung growth. FASEB Journal, 2013, 27, 723.1.	0.5	0
342	Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. Pulmonary Circulation, 2013, 3, 128-36.	1.7	6

#	Article	IF	Citations
343	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1354-1365.	2.4	108
344	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 409-419.	5.6	206
345	PAR-2 Inhibition Reverses Experimental Pulmonary Hypertension. Circulation Research, 2012, 110, 1179-1191.	4.5	61
346	Smoking: Is it a Risk Factor for Pulmonary Vascular Diseases?. Pulmonary Circulation, 2012, 2, 395-396.	1.7	13
347	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 897-908.	5.6	296
348	Micro-computed tomography imaging of composite nanoparticle distribution in the lung. International Journal of Pharmaceutics, 2012, 439, 230-233.	5.2	6
349	BDNF/TrkB Signaling Augments Smooth Muscle Cell Proliferation in Pulmonary Hypertension. American Journal of Pathology, 2012, 181, 2018-2029.	3.8	43
350	E-cadherin Controls Bronchiolar Progenitor Cells and Onset of Preneoplastic Lesions in Mice. Neoplasia, 2012, 14, 1164-IN31.	5.3	24
351	Activation of TRPC6 channels is essential for lung ischaemia–reperfusion induced oedema in mice. Nature Communications, 2012, 3, 649.	12.8	162
352	Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. Respiratory Medicine, 2012, 106, 308-313.	2.9	29
353	Megalin mediates transepithelial albumin clearance from the alveolar space of intact rabbit lungs. Journal of Physiology, 2012, 590, 5167-5181.	2.9	28
354	Paxillin Regulates Pulmonary Arterial Smooth Muscle Cell Function in Pulmonary Hypertension. American Journal of Pathology, 2012, 181, 1621-1633.	3.8	27
355	Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 272-280.	4.3	53
356	HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?. Journal of Heart and Lung Transplantation, 2012, 31, 1109-1114.	0.6	33
357	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	2.5	100
358	Matrix metalloproteinases and their inhibitors in pulmonary hypertension. European Respiratory Journal, 2012, 40, 766-782.	6.7	125
359	Tumor–stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opinion on Investigational Drugs, 2012, 21, 1107-1122.	4.1	30
360	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. Free Radical Biology and Medicine, 2012, 52, 1033-1042.	2.9	68

#	Article	IF	Citations
361	Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the AeronebÂ $^{\odot}$ Pro: Formulation aspects and nanoparticle stability to nebulization. International Journal of Pharmaceutics, 2012, 422, 398-408.	5.2	62
362	Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. Journal of Controlled Release, 2012, 157, 469-477.	9.9	50
363	Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. Journal of Controlled Release, 2012, 158, 329-335.	9.9	120
364	Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. Respiratory Research, 2012, 13, 7.	3.6	20
365	Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. Journal of Clinical Investigation, 2012, 122, 3652-3664.	8.2	93
366	Evolutionary Conserved Role of c-Jun-N-Terminal Kinase in CO2-Induced Epithelial Dysfunction. PLoS ONE, 2012, 7, e46696.	2.5	42
367	Comparative Proteomic Analysis of Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lung Transplant Donor Lungs. Journal of Proteome Research, 2011, 10, 2185-2205.	3.7	80
368	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	28.9	293
369	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333.	0.6	98
370	Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling. PLoS ONE, 2011, 6, e18136.	2.5	36
371	Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice. PLoS ONE, 2011, 6, e29093.	2.5	3
372	The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2011, 5, 195-206.	2.6	20
373	Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. Respiratory Research, 2011, 12, 20.	3.6	51
374	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2011, 12, 60.	3.6	66
375	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respiratory Research, 2011, 12, 87.	3.6	17
376	Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respiratory Research, 2011, 12, 99.	3.6	59
377	Amphiphilic, low molecular weight poly(ethylene imine) derivatives with enhanced stability for efficient pulmonary gene delivery. Journal of Gene Medicine, 2011, 13, 123-133.	2.8	33
378	Comparison of the Effects of Carbon Ion and Photon Irradiation on the Angiogenic Response in Human Lung Adenocarcinoma Cells. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1541-1549.	0.8	37

#	Article	IF	Citations
379	Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 341-350.	3.3	97
380	Shedding of Low-Density Lipoprotein Receptor–related Protein-1 in Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 438-448.	5.6	36
381	Nitric Oxide Inhibits Highly Selective Sodium Channels and the Na+/K+-ATPase in H441 Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 53-65.	2.9	36
382	Effects of short-term infusion of lipid emulsions on pro-inflammatory cytokines and lymphocyte apoptosis in septic and non-septic rats. British Journal of Nutrition, 2011, 106, 27-32.	2.3	1
383	Treprostinil Inhibits the Adhesion and Differentiation of Fibrocytes via the Cyclic Adenosine Monophosphate–Dependent and Ras-Proximate Protein–Dependent Inactivation of Extracellular Regulated Kinase. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 692-703.	2.9	29
384	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. Circulation, 2011, 123, 1194-1204.	1.6	42
385	Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Plateletâ€Derived Growth Factor Receptorâ€Î². Pulmonary Circulation, 2011, 1, 259-268.	1.7	44
386	Neurotrophic Tyrosine Kinase Receptor B/Neurotrophin 4 Signaling Axis Is Perturbed in Clinical and Experimental Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 768-780.	2.9	18
387	Exudate Macrophages Attenuate Lung Injury by the Release of IL-1 Receptor Antagonist in Gram-negative Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1380-1390.	5.6	94
388	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, 2011, 03, 87ra53.	12.4	59
389	Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models. Journal of Nanomaterials, 2011, 2011, 1-16.	2.7	26
390	Air Travel Can Be Safe and Well Tolerated in Patients with Clinically Stable Pulmonary Hypertension. Pulmonary Circulation, 2011, 1, 239-243.	1.7	21
391	Pulmonary Drug Delivery with Nanoparticles. , 2011, , .		1
392	Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. PLoS ONE, 2011, 6, e18883.	2.5	36
393	Dry powder aerosolization of a recombinant surfactant protein-Câ \in based surfactant for inhalative treatment of the acutely inflamed lung*. Critical Care Medicine, 2010, 38, 1584-1591.	0.9	36
394	Obstructive sleep apnea in a patient with the Melkersson–Rosenthal syndrome. Sleep and Breathing, 2010, 14, 245-247.	1.7	4
395	Amine-Modified Poly(Vinyl Alcohol)s as Non-viral Vectors for siRNA Delivery: Effects of the Degree of Amine Substitution on Physicochemical Properties and Knockdown Efficiency. Pharmaceutical Research, 2010, 27, 2670-2682.	3.5	22
396	Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respiratory Physiology and Neurobiology, 2010, 174, 282-291.	1.6	35

#	Article	IF	Citations
397	HIF-1α signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radical Biology and Medicine, 2010, 48, 1626-1635.	2.9	126
398	Novel â€~Nano in Nano' Composites for Sustained Drug Delivery: Biodegradable Nanoparticles Encapsulated into Nanofiber Nonâ€Wovens. Macromolecular Bioscience, 2010, 10, 1527-1535.	4.1	56
399	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine, 2010, 10, 26.	2.0	38
400	IL-1 Receptor Antagonist Exerts Anti-apoptotic And Barrier-protective Effects Towards Alveolar Epithelium In A Murine Model Of LPS-induced Acute Lung Injury. , 2010, , .		1
401	Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax, 2010, 65, 949-955.	5.6	66
402	TIAR and TIA-1 mRNA-Binding Proteins Co-aggregate under Conditions of Rapid Oxygen Decline and Extreme Hypoxia and Suppress the HIF-1Â Pathway. Journal of Molecular Cell Biology, 2010, 2, 345-356.	3.3	43
403	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	5.6	118
404	Safety and Tolerability of Inhaled Heparin in Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 161-172.	1.4	51
405	Worldwide Physician Education and Training in Pulmonary Hypertension. Chest, 2010, 137, 85S-94S.	0.8	26
406	INDUCTION OF LYMPHOCYTE APOPTOSIS IN A MURINE MODEL OF ACUTE LUNG INJURY-MODULATION BY LIPID EMULSIONS. Shock, 2010, 33, 179-188.	2.1	15
407	Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 611-619.	5.6	46
408	Dysregulation of the IL-13 Receptor System. A Novel Pathomechanism in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 805-818.	5.6	59
409	Epithelial Stress and Apoptosis Underlie Hermansky-Pudlak Syndrome–associated Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 207-219.	5.6	83
410	Pulmonary Targeting with Biodegradable Salbutamol-Loaded Nanoparticles. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 47-57.	1.4	60
411	Animal models of pulmonary hypertension: role in translational research. Drug Discovery Today: Disease Models, 2010, 7, 89-97.	1.2	11
412	Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 55, 1915-1922.	2.8	484
413	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. Respiratory Research, 2010, 11, 146.	3.6	22
414	Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. Respiratory Research, 2010, 11, 81.	3.6	13

#	Article	IF	Citations
415	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine, 2010, 104, 731-740.	2.9	72
416	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. Journal of Molecular and Cellular Cardiology, 2010, 49, 598-605.	1.9	56
417	Riociguat for pulmonary hypertension. Future Cardiology, 2010, 6, 155-166.	1.2	30
418	Fish oil-containing lipid emulsions in patients with sepsis. Critical Care, 2010, 14, 128.	5.8	9
419	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
420	Enhanced gene expression and reduced toxicity in mice using polyplexes of low-molecular-weight poly(ethylene imine) for pulmonary gene delivery. Journal of Drug Targeting, 2009, 17, 638-651.	4.4	21
421	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. Molecular Biology of the Cell, 2009, 20, 4751-4765.	2.1	84
422	Heme Oxygenase-2 and Large-Conductance Ca2+-activated K+Channels. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 353-364.	5.6	37
423	Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L442-L452.	2.9	87
424	Acute Lung Injury Is Reduced in <i>fat-1</i> Mice Endogenously Synthesizing n-3 Fatty Acids. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 474-483.	5.6	50
425	Macrophage Tumor Necrosis Factor-α Induces Epithelial Expression of Granulocyte–Macrophage Colony-stimulating Factor. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 521-532.	5.6	103
426	Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 780-787.	5.6	206
427	The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 683-691.	2.9	93
428	Lysyl Oxidase Activity Is Dysregulated during Impaired Alveolarization of Mouse and Human Lungs. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1239-1252.	5.6	76
429	Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L977-L983.	2.9	60
430	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L658-L665.	2.9	35
431	Genome-wide transcriptional profiling of mononuclear phagocytes recruited to mouse lungs in response to alveolar challenge with the TLR2 agonist Pam3CSK4. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L608-L618.	2.9	9
432	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L462-L469.	2.9	20

#	Article	IF	Citations
433	Carbon Monoxide Rapidly Impairs Alveolar Fluid Clearance by Inhibiting Epithelial Sodium Channels. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 639-650.	2.9	58
434	Amplification of Lipopolysaccharide-Induced Cytokine Synthesis in Non–Small Cell Lung Cancer/Neutrophil Cocultures. Molecular Cancer Research, 2009, 7, 1729-1735.	3.4	12
435	Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. Journal of Controlled Release, 2009, 140, 47-54.	9.9	51
436	Stabilization of Aerosolizable Nano-carriers by Freeze-Drying. Pharmaceutical Research, 2009, 26, 129-138.	3.5	35
437	Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. International Journal of Pharmaceutics, 2009, 367, 169-178.	5.2	109
438	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2009, 22, 50-56.	2.6	43
439	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	2.8	209
440	Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation. Journal of Cystic Fibrosis, 2009, 8, 338-347.	0.7	55
441	Transcriptome profiling of primary murine monocytes, lung macrophages and lung dendritic cells reveals a distinct expression of genes involved in cell trafficking. Respiratory Research, 2009, 10, 2.	3.6	30
442	Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. Neoplasia, 2009, 11, 48-56.	5.3	87
443	Alveolar Oxidative Stress is Associated with Elevated Levels of Nonenzymatic Low-Molecular-Weight Antioxidants in Patients with Different Forms of Chronic Fibrosing Interstitial Lung Diseases. Antioxidants and Redox Signaling, 2009, 11, 227-240.	5.4	46
444	Staphylococcus aureus α-toxin and Escherichia coli hemolysin impair cardiac regional perfusion and contractile function by activating myocardial eicosanoid metabolism in isolated rat hearts. Critical Care Medicine, 2009, 37, 2025-2032.	0.9	13
445	WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2009, 119, 772-87.	8.2	447
446	Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. Analytical and Bioanalytical Chemistry, 2008, 390, 697-714.	3.7	23
447	Direct and simultaneous profiling of epoxyeicosatrienoic acid enantiomers by capillary tandem column chiral-phase liquid chromatography with dual online photodiode array and tandem mass spectrometric detection. Analytical and Bioanalytical Chemistry, 2008, 392, 717-726.	3.7	19
448	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulmonary Medicine, 2008, 8, 25.	2.0	36
449	Effects of cellâ€penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs. Journal of Gene Medicine, 2008, 10, 1236-1246.	2.8	76
450	TGFâ€Î² signaling is dynamically regulated during the alveolarization of rodent and human lungs. Developmental Dynamics, 2008, 237, 259-269.	1.8	89

#	Article	IF	CITATIONS
451	Pulmonary absorption of aerosolized fluorescent markers in the isolated rabbit lung. International Journal of Pharmaceutics, 2008, 351, 158-164.	5.2	20
452	Executive functions and cognitive subprocesses in patients with obstructive sleep apnoea. Journal of Sleep Research, 2008, 17, 271-280.	3.2	61
453	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 824-832.	2.6	64
454	Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. International Journal of Biochemistry and Cell Biology, 2008, 40, 1872-1882.	2.8	33
455	Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: Impact on adhesion and apoptosis. Atherosclerosis, 2008, 197, 630-637.	0.8	24
456	NOX4 Regulates ROS Levels Under Normoxic and Hypoxic Conditions, Triggers Proliferation, and Inhibits Apoptosis in Pulmonary Artery Adventitial Fibroblasts. Antioxidants and Redox Signaling, 2008, 10, 1687-1698.	5.4	118
457	A Search for Subgroups of Patients With ARDS Who May Benefit From Surfactant Replacement Therapy. Chest, 2008, 134, 724-732.	0.8	109
458	Clinical Aspects of Acute Lung Insufficiency (ALI/TRALI). Transfusion Medicine and Hemotherapy, 2008, 35, 80-88.	1.6	10
459	Transgelin is a direct target of TGFâ€Î²/Smad3â€dependent epithelial cell migration in lung fibrosis. FASEB Journal, 2008, 22, 1778-1789.	0.5	121
460	Functional role and species-specific contribution of arginases in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L34-L45.	2.9	74
461	Fhl-1, a New Key Protein in Pulmonary Hypertension. Circulation, 2008, 118, 1183-1194.	1.6	79
462	Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 838-846.	5.6	447
463	Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. Journal of Experimental Medicine, 2008, 205, 3065-3077.	8.5	323
464	PKR Regulates TLR2/TLR4-Dependent Signaling in Murine Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 26-31.	2.9	70
465	Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 163-170.	2.9	14
466	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 188-196.	5.6	82
467	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 1-12.	1.4	76
468	Intravascular and Extravascular Coagulation and Fibrinolysis in the Diseased Lung., 2008,, 37-47.		0

#	Article	IF	CITATIONS
469	Fish oil in critical illness. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 121-127.	2.5	77
470	APOPTOSIS CONTRIBUTES TO SEPTIC CARDIOMYOPATHY AND IS IMPROVED BY SIMVASTATIN THERAPY. Shock, 2008, 29, 497-503.	2.1	56
471	The lectin-like domain of tumor necrosis factor-α improves alveolar fluid balance in injured isolated rabbit lungs*. Critical Care Medicine, 2008, 36, 1543-1550.	0.9	61
472	Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase. Thrombosis and Haemostasis, 2008, 100, 1185-1192.	3.4	5
473	Functional Wnt Signaling Is Increased in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2008, 3, e2142.	2.5	429
474	AMP-activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. Journal of Clinical Investigation, 2008, 118, 752-62.	8.2	146
475	Inhaled Prostanoids in the Therapy of Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
476	Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase. Thrombosis and Haemostasis, 2008, 100, 1185-92.	3.4	2
477	Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2957-2968.	1.6	46
478	Lung Dendritic Cells Elicited by Fms-like Tyrosin 3-Kinase Ligand Amplify the Lung Inflammatory Response to Lipopolysaccharide. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 892-901.	5.6	27
479	Importance of Phosphoinositide 3-Kinase \hat{l}^3 in the Host Defense against Pneumococcal Infection. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 958-966.	5.6	73
480	The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 640-650.	2.9	82
481	Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. Circulation Research, 2007, 101, 258-267.	4.5	317
482	Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax, 2007, 62, 588-594.	5.6	66
483	Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2331-2339.	1.6	139
484	Hyperoxia modulates TGF- \hat{l}^2 /BMP signaling in a mouse model of bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L537-L549.	2.9	212
485	Immune modulation by parenteral lipids: Platelet activating factor is not the only clue. Critical Care Medicine, 2007, 35, 1444-1445.	0.9	2
486	Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injuryâ€"Role of platelet-activating factor receptor. Critical Care Medicine, 2007, 35, 544-554.	0.9	28

#	Article	IF	Citations
487	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respiratory Physiology and Neurobiology, 2007, 159, 196-201.	1.6	32
488	Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide. Respiratory Medicine, 2007, 101, 2125-2132.	2.9	27
489	Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1072-1078.	2.4	127
490	lloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respiratory Research, 2007, 8, 4.	3.6	34
491	Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respiratory Research, 2007, 8, 55.	3.6	66
492	Non-invasive screening of lung nodules in mice comparing a novel volumetric computed tomography with a clinical multislice CT. Oncology Reports, 2007, , .	2.6	3
493	Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thrombosis and Haemostasis, 2007, 97, 774-787.	3.4	81
494	Temporal and spatial regulation of bone morphogenetic protein signaling in late lung development. Developmental Dynamics, 2007, 236, 2825-2835.	1.8	37
495	Alveolar fluid clearance in acute lung injury: what have we learned from animal models and clinical studies?. Intensive Care Medicine, 2007, 33, 1229-1240.	8.2	56
496	lloprost-Containing Liposomes for Aerosol Application in Pulmonary Arterial Hypertension: Formulation Aspects and Stability. Pharmaceutical Research, 2007, 24, 277-287.	3.5	78
497	Akutes respiratorisches Distress-Syndrom (ARDS). , 2007, , 1177-1183.		0
498	Non-invasive screening of lung nodules in mice comparing a novel volumetric computed tomography with a clinical multislice CT. Oncology Reports, 2007, 17, 707-12.	2.6	8
499	Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thrombosis and Haemostasis, 2007, 97, 774-87.	3.4	25
500	Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 353-363.	1.2	17
501	Endotoxin induced peritonitis elicits monocyte immigration into the lung: implications on alveolar space inflammatory responsiveness. Respiratory Research, 2006, 7, 30.	3.6	17
502	DNA Transfer into Human Lung Cells Is Improved with Tatâ^'RGD Peptide by Caveoli-Mediated Endocytosis. Bioconjugate Chemistry, 2006, 17, 327-334.	3.6	36
503	Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 48, 1433-1437.	2.8	115
504	Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681.	2.8	135

#	Article	IF	CITATIONS
505	Human RELMÎ ² is a mitogenic factor in lung cells and induced in hypoxia. FEBS Letters, 2006, 580, 900-903.	2.8	33
506	Liver carboxylesterase cleaves surfactant protein (SP-) B and promotes surfactant subtype conversion. Biochemical and Biophysical Research Communications, 2006, 348, 1449-1454.	2.1	11
507	Constitutive homo- and hetero-oligomerization of TβRII-B, an alternatively spliced variant of the mouse TGF-β type II receptor. Biochemical and Biophysical Research Communications, 2006, 351, 651-657.	2.1	6
508	Hybrid-Primed Lymphocytes and Hybrid Vaccination Prevent Tumor Growth of Lewis Lung Carcinoma in Mice. Journal of Immunotherapy, 2006, 29, 175-187.	2.4	13
509	Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome. Critical Care Medicine, 2006, 34, 2370-2376.	0.9	26
510	Effect of PEGylation on the Stability of Liposomes During Nebulisation and in Lung Surfactant. Journal of Nanoscience and Nanotechnology, 2006, 6, 3010-3016.	0.9	43
511	Lipoteichoic acid (LTA) from Staphylococcus aureus stimulates human neutrophil cytokine release by a CD14-dependent, Toll-like-receptor-independent mechanism: Autocrine role of tumor necrosis factor- \hat{l}_{\pm} in mediating LTA-induced interleukin-8 generation. Critical Care Medicine, 2006, 34, 835-841.	0.9	50
512	Fish oil in the critically ill: from experimental to clinical data. Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, 140-148.	2.5	73
513	Free arachidonic versus eicosapentaenoic acid differentially influences the potency of bacterial exotoxins to provoke myocardial depression in isolated rat hearts. Critical Care Medicine, 2006, 34, 118-126.	0.9	36
514	Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 149.	3.9	33
515	Circulating adrenomedullin in obstructive sleep apnoea. Journal of Sleep Research, 2006, 15, 89-95.	3.2	17
516	Mutations of the TGF- \hat{l}^2 type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368
517	Antioxidant Vitamin C Improves Endothelial Function in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 897-901.	5.6	167
518	Genetic Association of the Serotonin Transporter in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 793-797.	5.6	88
519	Impact of Mitochondria and NADPH Oxidases on Acute and Sustained Hypoxic Pulmonary Vasoconstriction. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 505-513.	2.9	90
520	Hypoxia in lung vascular biology and disease. Cardiovascular Research, 2006, 71, 618-619.	3.8	5
521	Oxygen sensors in hypoxic pulmonary vasoconstriction. Cardiovascular Research, 2006, 71, 620-629.	3.8	61
522	Hypoxia- and non-hypoxia-related pulmonary hypertension â€" Established and new therapies. Cardiovascular Research, 2006, 72, 30-40.	3.8	49

#	Article	IF	CITATIONS
523	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
524	Resident Alveolar Macrophages Are Replaced by Recruited Monocytes in Response to Endotoxin-Induced Lung Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 227-235.	2.9	161
525	Systematic Comparison of the T7-IVT and SMART-Based RNA Preamplification Techniques for DNA Microarray Experiments. Clinical Chemistry, 2006, 52, 1161-1167.	3.2	26
526	Alveolar Epithelial Cells Direct Monocyte Transepithelial Migration upon Influenza Virus Infection: Impact of Chemokines and Adhesion Molecules. Journal of Immunology, 2006, 177, 1817-1824.	0.8	190
527	Impact of HIFâ€1α and HIFâ€2α on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. FASEB Journal, 2006, 20, 163-165.	0.5	52
528	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19093-19098.	7.1	273
529	Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells. Circulation Research, 2006, 98, 1072-1080.	4.5	207
530	Long chain triglyceride (LCT)â€based lipid emulsions increase and olive oil(OO)â€based lipid emulsions decrease leukocyte invasion and mortality in a model of acute lung injury. FASEB Journal, 2006, 20, A1055.	0.5	0
531	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thrombosis and Haemostasis, 2006, 95, 720-7.	3.4	7
532	Hypoxic pulmonary vasoconstriction-triggered by an increase in reactive oxygen species?. Novartis Foundation Symposium, 2006, 272, 196-208; discussion 208-17.	1.1	7
533	Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive―structural and functional changes in mice, both in normoxia and hypoxia. Thrombosis and Haemostasis, 2005, 94, 630-638.	3.4	31
534	CCR2-positive monocytes recruited to inflamed lungs downregulate local CCL2 chemokine levels. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L350-L358.	2.9	75
535	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB Journal, 2005, 19, 1175-1177.	0.5	158
536	Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 358-363.	5.6	62
537	The Inflammatory versus Constitutive Trafficking of Mononuclear Phagocytes into the Alveolar Space of Mice Is Associated with Drastic Changes in Their Gene Expression Profiles. Journal of Immunology, 2005, 175, 1884-1893.	0.8	79
538	Thrombin Impairs Alveolar Fluid Clearance by Promoting Endocytosis of Na+,K+-ATPase. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 343-354.	2.9	64
539	Oleic Acid Inhibits Alveolar Fluid Reabsorption. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 469-479.	5.6	72
540	Moraxella catarrhalis–Infected Alveolar Epithelium Induced Monocyte Recruitment and Oxidative Burst. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 157-166.	2.9	16

#	Article	IF	CITATIONS
541	Role of Hypoxia-Inducible Factor-1α in Hypoxia-Induced Apoptosis of Primary Alveolar Epithelial Type II Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 395-403.	2.9	87
542	Mechanisms of Cardiac Depression Caused by Lipoteichoic Acids FromStaphylococcus aureusin Isolated Rat Hearts. Circulation, 2005, 112, 691-698.	1.6	21
543	Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation. Journal of Leukocyte Biology, 2005, 78, 992-1000.	3.3	24
544	Hypoxiaâ€driven proliferation of human pulmonary artery fibroblasts: crossâ€ŧalk between HIF‶α and an autocrine angiotensin system. FASEB Journal, 2005, 19, 1-26.	0.5	72
545	HIF-1α attenuates tumor growth in spite of augmented vascularization in an A549 adenocarcinoma mouse model. International Journal of Oncology, 2005, 27, 393.	3.3	8
546	Tropolysin, a New Oligopeptidase from African Trypanosomesâ€,‡. Biochemistry, 2005, 44, 14658-14669.	2.5	10
547	Transforming Growth Factor- \hat{I}^2 -Dependent Growth Inhibition in Primary Vascular Smooth Muscle Cells Is p38-Dependent. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1005-1012.	2.5	92
548	Oligopeptidase B from Trypanosoma evansi. Journal of Biological Chemistry, 2005, 280, 10925-10937.	3 . 4	62
549	Identification of novel Nox4 splice variants with impact on ROS levels in A549 cells. Biochemical and Biophysical Research Communications, 2005, 329, 32-39.	2.1	88
550	Analysis of Tumor Vessel Supply in Lewis Lung Carcinoma in Mice by Fluorescent Microsphere Distribution and Imaging with Micro- and Flat-Panel Computed Tomography. American Journal of Pathology, 2005, 167, 937-946.	3.8	32
551	Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respiratory Research, 2005, 6, 109.	3.6	99
552	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respiratory Research, 2005, 6, 128.	3 . 6	34
553	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respiratory Research, 2005, 6, 76.	3.6	31
554	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. Respiratory Research, 2005, 6, 86.	3.6	32
555	Imatinib for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 1412-1413.	27.0	440
556	Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 2005, 115, 2811-2821.	8.2	917
557	HIF-1alpha attenuates tumor growth in spite of augmented vascularization in an A549 adenocarcinoma mouse model. International Journal of Oncology, 2005, 27, 393-400.	3.3	8
558	Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thrombosis and Haemostasis, 2004, 92, 529-540.	3.4	40

#	Article	IF	Citations
559	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 39-45.	5.6	230
560	Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. Circulation Research, 2004, 94, 1101-1108.	4.5	97
561	Measurement of exhaled hydrogen peroxide from rabbit lungs. Biological Chemistry, 2004, 385, 259-264.	2.5	9
562	Pneumolysin-Induced Lung Injury Is Independent of Leukocyte Trafficking into the Alveolar Space. Journal of Immunology, 2004, 173, 1307-1312.	0.8	79
563	Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation. Chest, 2004, 125, 344-347.	0.8	13
564	Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis. Toxicology and Applied Pharmacology, 2004, 195, 218-231.	2.8	45
565	Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 344-354.	0.8	30
566	Bronchoscopic surfactant administration preserves gas exchange and pulmonary compliance after single lung transplantation in dogs. Journal of Thoracic and Cardiovascular Surgery, 2004, 127, 335-343.	0.8	24
567	Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153.		119
568	Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. Free Radical Biology and Medicine, 2004, 36, 78-89.	2.9	14
569	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radical Biology and Medicine, 2004, 36, 1279-1288.	2.9	183
570	Identification of proteins in laser-microdissected small cell numbers by SELDI-TOF and Tandem MS. BMC Biotechnology, 2004, 4, 30.	3.3	28
571	Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12.	2.8	1,542
572	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S81-S88.	2.8	206
573	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 44, 1488-1496.	2.8	134
574	Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. Thrombosis and Haemostasis, 2004, 92, 1402-1410.	3.4	189
575	Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome. New England Journal of Medicine, 2004, 351, 884-892.	27.0	414
576	Basic features of hypoxic pulmonary vasoconstriction in mice. Respiratory Physiology and Neurobiology, 2004, 139, 191-202.	1.6	58

#	Article	IF	CITATIONS
577	Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp. Annals of Internal Medicine, 2004, 141, 169.	3.9	271
578	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension., 2004, , 163-168.		0
579	ï‰-3 vs. ï‰-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Medicine, 2003, 29, 1472-1481.	8.2	167
580	Central sleep apnoea and unilateral diaphragmatic paralysis associated with vertebral artery compression of the medulla oblongata. Journal of Neurology, 2003, 250, 503-505.	3.6	18
581	Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release, 2003, 86, 131-144.	9.9	151
582	Impact of surface tension on the conversion rate of large to small surfactant aggregates. Biophysical Chemistry, 2003, 104, 229-238.	2.8	4
583	Cyclooxygenase-2–Dependent and Thromboxane-Dependent Vascular and Bronchial Responses are Regulated via p38 Mitogen-Activated Protein Kinase in Control and Endotoxin-Primed Rat Lungs. Laboratory Investigation, 2003, 83, 333-347.	3.7	12
584	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 42, 158-164.	2.8	359
585	RNA interference for HIF- $1\hat{l}\pm$ inhibits its downstream signalling and affects cellular proliferation. Biochemical and Biophysical Research Communications, 2003, 312, 571-577.	2.1	68
586	Sildenafil for lung fibrosis and pulmonary hypertension. Lancet, The, 2003, 361, 263.	13.7	0
587	Obstructive Sleep Apnea Due to HIV-Associated Lipodystrophy. Clinical Infectious Diseases, 2003, 37, 1398-1399.	5.8	14
588	Circulating Vascular Progenitor Cells Do Not Contribute to Compensatory Lung Growth. Circulation Research, 2003, 93, 372-379.	4.5	79
589	Parenteral Nutrition with Fish Oil Modulates Cytokine Response in Patients with Sepsis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1321-1328.	5.6	219
590	Monocytes Are Potent Facilitators of Alveolar Neutrophil Emigration During Lung Inflammation: Role of the CCL2-CCR2 Axis. Journal of Immunology, 2003, 170, 3273-3278.	0.8	184
591	Short-Time Infusion of Fish Oil-Based Lipid Emulsions, Approved for Parenteral Nutrition, Reduces Monocyte Proinflammatory Cytokine Generation and Adhesive Interaction with Endothelium in Humans. Journal of Immunology, 2003, 171, 4837-4843.	0.8	170
592	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H931-H938.	3.2	34
593	Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1139-1141.	5.6	265
594	Effects of Mitochondrial Inhibitors and Uncouplers on Hypoxic Vasoconstriction in Rabbit Lungs. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 721-732.	2.9	51

#	Article	IF	Citations
595	Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1358-1365.	5.6	167
596	Selective Inhibition of Large-to-Small Surfactant Aggregate Conversion by Serine Protease Inhibitors of the bis-Benzamidine Type. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 95-102.	2.9	8
597	Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children. Critical Care Medicine, 2003, 31, 284-290.	0.9	25
598	Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts*. Critical Care Medicine, 2003, 31, 683-688.	0.9	19
599	Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion. Transplantation, 2003, 75, 814-821.	1.0	7
600	Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. Thrombosis and Haemostasis, 2003, 89, 53-64.	3.4	17
601	Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost. Thrombosis and Haemostasis, 2003, 90, 1141-1149.	3.4	47
602	Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L69-L76.	2.9	4
603	Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. Thrombosis and Haemostasis, 2003, 89, 53-64.	3.4	1
604	Interaction of Antibodies to Proteinase 3 (Classic Anti-Neutrophil Cytoplasmic Antibody) with Human Renal Tubular Epithelial Cells: Impact on Signaling Events and Inflammatory Mediator Generation. Journal of Immunology, 2002, 168, 3057-3064.	0.8	10
605	Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 741-745.	2.5	23
606	Serum Levels of Vascular Endothelial Growth Factor Are Elevated in Patients with Obstructive Sleep Apnea and Severe Nighttime Hypoxia. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 67-70.	5.6	206
607	Apical, But Not Basolateral, Endotoxin Preincubation Protects Alveolar Epithelial Cells Against Hydrogen Peroxide-Induced Loss of Barrier Function: The Role of Nitric Oxide Synthesis. Journal of Immunology, 2002, 169, 1474-1481.	0.8	16
608	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
609	Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus α-Toxin. Circulation, 2002, 106, 2104-2110.	1.6	146
610	Molecular Pathways of Monocyte Emigration into the Alveolar Air Space of Intact Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 95-100.	5.6	47
611	The Role of CC Chemokine Receptor 2 in Alveolar Monocyte and Neutrophil Immigration in Intact Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 268-273.	5.6	179
612	An ELISA Technique for Quantification of Surfactant Apoprotein (SP)-C in Bronchoalveolar Lavage Fluid. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 470-474.	5.6	57

#	Article	IF	CITATIONS
613	A doubleâ€blind, randomized, placeboâ€controlled trial of nâ€3 versus nâ€6 fatty acidâ€based lipid infusion in atopic dermatitis. Journal of Parenteral and Enteral Nutrition, 2002, 26, 151-158.	2.6	62
614	Adrenomedullin Reduces Endothelial Hyperpermeability. Circulation Research, 2002, 91, 618-625.	4.5	167
615	Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cellsâ€role of hypoxiaâ€inducible transcription factors. FASEB Journal, 2002, 16, 1660-1661.	0.5	98
616	ï‰-3 Fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H811-H818.	3.2	103
617	Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L1245-L1252.	2.9	113
618	Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension. Annals of Internal Medicine, 2002, 136, 515.	3.9	446
619	Staphylococcus Aureus Alpha Toxin Mediates Polymorphonuclear Leukocyte-Induced Vasocontraction and Endothelial Dysfunction. Shock, 2002, 17, 30-35.	2.1	15
620	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine, 2002, 30, 2489-2492.	0.9	69
621	Mediator generation and signaling events in alveolar epithelial cells attacked by <i>S. aureus </i> l±-toxin. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L207-L214.	2.9	57
622	Distinct pathways of lipopolysaccharide priming of human neutrophil respiratory burst: Role of lipid mediator synthesis and sensitivity to interleukin-10. Critical Care Medicine, 2002, 30, 2306-2312.	0.9	13
623	Chemical Coupling of a Monoclonal Antisurfactant Protein-B Antibody to Human Urokinase for Targeting Surfactant-Incorporating Alveolar Fibrin. Bioconjugate Chemistry, 2002, 13, 804-811.	3.6	9
624	cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue. American Journal of Pathology, 2002, 160, 81-90.	3.8	75
625	Genomic Organization and Regulation of a Human 7-Helix Transmembrane Receptor Which Is Expressed in Pulmonary Epithelial Cells and Induced in Hypoxia. Biochemical and Biophysical Research Communications, 2002, 291, 1160-1165.	2.1	15
626	Aerosolized Vasodilators in Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 117-122.	1.2	19
627	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet, The, 2002, 360, 895-900.	13.7	720
628	Staphylococcal \hat{l} ±-toxin provokes neutrophil-dependent cardiac dysfunction: role of ICAM-1 and cys-leukotrienes. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1157-H1165.	3.2	6
629	Obstructive Sleep Apnoea Secondary to Superior Vena Cava Thrombosis in a Patient with Activated Protein C Resistance. Obstruktive Schlaf-Apnoe infolge einer Thrombose der oberen Hohlvene bei einem Patienten mit Resistenz gegenuber aktiviertem Protein C. Somnologie, 2002, 6, 173-175.	1.5	1
630	Cell-Specific Nitric Oxide Synthase-Isoenzyme Expression and Regulation in Response to Endotoxin in Intact Rat Lungs. Laboratory Investigation, 2002, 82, 425-441.	3.7	70

#	Article	IF	CITATIONS
631	In vitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFα impact of ω-3 versus ω-6 fatty acids. Journal of Lipid Research, 2002, 43, 944-951.	4.2	39
632	Linkage Analysis in a Large Family With Primary Pulmonary Hypertension. Chest, 2002, 121, 54S-56S.	0.8	18
633	In vitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFalpha impact of omega-3 versus omega-6 fatty acids. Journal of Lipid Research, 2002, 43, 944-51.	4.2	30
634	Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation. Journal of Leukocyte Biology, 2002, 71, 996-1004.	3.3	30
635	Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. Journal of the American College of Cardiology, 2001, 38, 1130-1136.	2.8	56
636	Comparison of Different Detection Methods in Quantitative Microdensitometry. American Journal of Pathology, 2001, 158, 407-417.	3.8	34
637	Surfactant alteration and replacement in acute respiratory distress syndrome. Respiratory Research, 2001, 2, 353.	3.6	199
638	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L638-L645.	2.9	59
639	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L792-L800.	2.9	17
640	Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L58-L68.	2.9	119
641	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L896-L904.	2.9	23
642	Hypoxic pulmonary vasoconstriction: a multifactorial response?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L314-L317.	2.9	40
643	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1361-L1368.	2.9	37
644	PROTECTION AGAINST GAS EXCHANGE ABNORMALITIES BY PRE-AEROSOLIZED PGE 1, ILOPROST AND NITROPRUSSIDE IN LUNG ISCHEMIA-REPERFUSION1. Transplantation, 2001, 71, 185-193.	1.0	35
645	Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Medicine, 2001, 27, 1699-1717.	8.2	141
646	Cellular pathophysiology and therapy of pulmonary hypertension. Translational Research, 2001, 138, 367-377.	2.3	57
647	Physiologic basis for the treatment of pulmonary hypertension. Translational Research, 2001, 138, 287-297.	2.3	81
648	Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus α-toxin. Critical Care Medicine, 2001, 29, 1-7.	0.9	29

#	Article	IF	CITATIONS
649	Human Endothelial Cell Activation and Mediator Release in Response to Listeria monocytogenes Virulence Factors. Infection and Immunity, 2001, 69, 897-905.	2.2	67
650	Cell Density Regulates Neutrophil IL-8 Synthesis: Role of IL-1 Receptor Antagonist and Soluble TNF Receptors. Journal of Immunology, 2001, 166, 6287-6293.	0.8	30
651	Pathophysiology of Acute Lung Injury. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 247-258.	2.1	34
652	Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1694-1700.	5.6	54
653	Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 219-225.	2.9	22
654	Alveolar JE/MCP-1 and Endotoxin Synergize to Provoke Lung Cytokine Upregulation, Sequential Neutrophil and Monocyte Influx, and Vascular Leakage in Mice. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 406-411.	5.6	74
655	Endogenous Nitric Oxide Synthesis and Vascular Leakage in Ischemic-Reperfused Rabbit Lungs. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 412-418.	5.6	17
656	Alteration of Fatty Acid Profiles in Different Pulmonary Surfactant Phospholipids in Acute Respiratory Distress Syndrome and Severe Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 95-100.	5.6	137
657	SHORT-TERM ???PRECONDITIONING??? WITH INHALED NITRIC OXIDE PROTECTS RABBIT LUNGS AGAINST ISCHEMIA-REPERFUSION INJURY1. Transplantation, 2001, 72, 1363-1370.	1.0	34
658	Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial. Annals of Internal Medicine, 2000, 132, 435.	3.9	229
659	Immunostaining and Laser-Assisted Cell Picking for mRNA Analysis. Laboratory Investigation, 2000, 80, 327-333.	3.7	57
660	The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L496-L502.	2.9	12
661	Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L25-L35.	2.9	171
662	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H ₂ O ₂ ?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L683-L690.	2.9	87
663	PAF-induced synthesis of tetraenoic and pentaenoic leukotrienes in the isolated rabbit lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L268-L275.	2.9	18
664	Cell Type-Specific mRNA Quantitation in Non-Neoplastic Tissues after Laser-Assisted Cell Picking. Pathobiology, 2000, 68, 191-195.	3.8	22
665	The Effect of Repeated Ozone Exposures on Inflammatory Markers in Bronchoalveolar Lavage Fluid and Mucosal Biopsies. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1855-1861.	5.6	123
666	Nitric Oxide (NO)–Dependent but Not NO-Independent Guanylate Cyclase Activation Attenuates Hypoxic Vasoconstriction in Rabbit Lungs. American Journal of Respiratory Cell and Molecular Biology, 2000, 23, 222-227.	2.9	24

#	Article	IF	Citations
667	Differential Impact of Ultrasonically Nebulized Versus Tracheal-instilled Surfactant on Ventilation-Perfusion (V˙A/Q˙) Mismatch in a Model of Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 152-159.	5.6	29
668	Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 454-462.	5.6	334
669	Synthesis of Arachidonic Acid–Derived Lipoxygenase and Cytochrome P450 Products in the Intact Human Lung Vasculature. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1917-1923.	5.6	44
670	Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 566-570.	5.6	574
671	Monocyte Migration Through the Alveolar Epithelial Barrier: Adhesion Molecule Mechanisms and Impact of Chemokines. Journal of Immunology, 2000, 164, 427-435.	0.8	120
672	Staphylococcal \hat{l}_{\pm} -Toxin Provokes Coronary Vasoconstriction and Loss in Myocardial Contractility in Perfused Rat Hearts. Circulation, 2000, 101, 78-85.	1.6	61
673	Endotoxin-Induced Myocardial Tumor Necrosis Factor-α Synthesis Depresses Contractility of Isolated Rat Hearts. Circulation, 2000, 102, 2758-2764.	1.6	143
674	Immunostaining for Cell Picking and Real-Time mRNA Quantitation. American Journal of Pathology, 2000, 157, 1459-1466.	3.8	51
675	Rat Pulmonary Cyclooxygenase-2 Expression in Response to Endotoxin Challenge. American Journal of Pathology, 2000, 156, 1275-1287.	3.8	39
676	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. Journal of the American College of Cardiology, 2000, 35, 176-182.	2.8	296
677	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L90-L95.	2.9	43
678	Cleavage of Surfactant-Incorporating Fibrin by Different Fibrinolytic Agents. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 738-745.	2.9	14
679	Role of Actin Depolymerization in the Surfactant Secretory Response of Alveolar Epithelial Type II Cells. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 206-212.	5.6	42
680	Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1500-1506.	5 . 6	73
681	Prostacyclin Enhances Stretch-induced Surfactant Secretion in Alveolar Epithelial Type II Cells. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 846-851.	5.6	36
682	Surfactant Subtype Conversion Is Related to Loss of Surfactant Apoprotein B and Surface Activity in Large Surfactant Aggregates. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 244-251.	5.6	51
683	Severe Microcirculatory Abnormalities Elicited by <i>E. coli </i> Hemolysin in the Rabbit Ileum Mucosa. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1171-1178.	5.6	21
684	Ventilation–Perfusion Mismatch after Lung Ischemia–Reperfusion. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1179-1187.	5.6	34

#	Article	IF	CITATIONS
685	Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 600-607.	5.6	369
686	Role of <i>Listeria monocytogenes</i> Exotoxins Listeriolysin and Phosphatidylinositol-Specific Phospholipase C in Activation of Human Neutrophils. Infection and Immunity, 1999, 67, 1125-1130.	2.2	56
687	Real-time quantitative RT–PCR after laser-assisted cell picking. Nature Medicine, 1998, 4, 1329-1333.	30.7	547
688	Effects of arachidonic acid metabolism on hypoxic vasoconstriction in rabbit lungs. European Journal of Pharmacology, 1998, 356, 231-237.	3.5	16
689	Simultaneous Analysis of 4- and 5-Series Lipoxygenase and Cytochrome P450 Products from Different Biological Sources by Reversed-Phase High-Performance Liquid Chromatographic Technique. Analytical Biochemistry, 1998, 261, 16-28.	2.4	34
690	ω-3 Fatty acid–based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial. Journal of the American Academy of Dermatology, 1998, 38, 539-547.	1.2	128
691	Nitric Oxide Biosynthesis in an Exotoxin-induced Septic Lung Model. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 498-504.	5.6	16
692	Abnormalities of Gastric Mucosal Oxygenation in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1586-1592.	5.6	157
693	Vascular Distension and Continued Ventilation Are Protective in Lung Ischemia/Reperfusion. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 171-177.	5.6	29
694	Wegener's Granulomatosis: Anti–proteinase 3 Antibodies Are Potent Inductors of Human Endothelial Cell Signaling and Leakage Response. Journal of Experimental Medicine, 1998, 187, 497-503.	8.5	64
695	Use of fish oil to prevent graft rejection. Proceedings of the Nutrition Society, 1998, 57, 577-585.	1.0	8
696	Nitro blue tetrazolium inhibits but does not mimic hypoxic vasoconstriction in isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L721-L727.	2.9	24
697	Clinical use of lipids to control inflammatory disease. Current Opinion in Clinical Nutrition and Metabolic Care, 1998, 1, 179-184.	2.5	28
698	Synergism Between Endotoxin Priming and Exotoxin Challenge in Provoking Severe Vascular Leakage in Rabbit Lungs. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 819-824.	5.6	10
699	Endotoxin priming of thromboxane-related vasoconstrictor responses in perfused rabbit lungs. Journal of Applied Physiology, 1997, 83, 18-24.	2.5	14
700	Effect of 3 hours of passive smoke exposure in the evening on inflammatory markers in bronchoalveolar and nasal lavage fluid in subjects with mild asthma. International Archives of Occupational and Environmental Health, 1997, 70, 85-93.	2.3	12
701	Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. British Journal of Haematology, 1996, 93, 707-713.	2.5	178
702	Hypoxic vasoconstriction in buffer-perfused rabbit lungs. Respiration Physiology, 1995, 100, 159-169.	2.7	71

#	Article	IF	CITATIONS
703	Hydrogen Peroxide-Induced Increase in Lung Endothelial and Epithelial Permeability-Effect of Adenylate Cyclase Stimulation and Phosphodiesterase Inhibition. Microvascular Research, 1995, 50, 1-17.	2.5	57
704	Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection. Medical Microbiology and Immunology, 1994, 183, 119-44.	4.8	25
705	[57] Adult respiratory distress syndrome: Model systems using isolated perfused rabbit lungs. Methods in Enzymology, 1994, 233, 549-584.	1.0	67
706	Computer-assisted morphometry of the intracapillary leukocyte pool in the rabbit lung. Cell and Tissue Research, 1993, 271, 469-476.	2.9	22
707	Proteolytic Cleavage of Fibrinogen: Amplification of Its Surfactant Inhibitory Capacity. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 239-247.	2.9	28
708	Endotoxin Primes Perfused Rabbit Lungs for Enhanced Vasoconstrictor Response to Staphylococcal α-Toxin. The American Review of Respiratory Disease, 1993, 148, 1179-1186.	2.9	21
709	Lung Surfactant Phospholipids Associate with Polymerizing Fibrin: Loss of Surface Activity. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 213-220.	2.9	83
710	Type II Alveolar Epithelial Eicosanoid Metabolism: Predominance of Cyclooxygenase Pathways and Transcellular Lipoxygenase Metabolism in Co-culture with Neutrophils. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 9-16.	2.9	37
711	Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro $\hat{a} \in \text{``accessor}$ comparison to natural surfactant. Lipids and Lipid Metabolism, 1991, 1081, 45-52.	2.6	30
712	Procoagulant activity in bronchoalveolar lavage of severely traumatized patients-relation to the development of acute respiratory distress. Thrombosis Research, 1991, 61, 53-64.	1.7	31
713	Lung Vascular Injury after Administration of Viable Hemolysin-formingEscherichia coliin Isolated Rabbit Lungs. The American Review of Respiratory Disease, 1991, 143, 797-805.	2.9	33
714	Local Complement Activation, Thromboxane-mediated Vasoconstriction, and Vascular Leakage in Isolated Lungs: Role of the Terminal Complement Sequence. The American Review of Respiratory Disease, 1989, 139, 88-99.	2.9	31
715	Surfactant Abnormalities in Patients with Respiratory Failure after Multiple Trauma. The American Review of Respiratory Disease, 1989, 140, 1033-1039.	2.9	219
716	Effects of alpha-tocopherol, its carboxylic acid chromane compound and two novel antioxidant isoflavanones on prostaglandin H synthase activity and autodeactivation. Naunyn-Schmiedeberg's Archives of Pharmacology, 1988, 338, 74-81.	3.0	4
717	A Highly Sensitive Gas Chromatographic Method Does not Detect Exhalation of Volatile Hydrocarbons from Isolated Ventilated Lungs under Massive Peroxidative Stress. Experimental Lung Research, 1988, 14, 387-401.	1.2	8
718	Role of Membrane Lipids in the Pulmonary Vascular Abnormalities Caused by Bacterial Toxins. The American Review of Respiratory Disease, 1987, 136, 462-466.	2.9	33
719	Arachidonic Acid Lipoxygenase Pathways and Increased Vascular Permeability in Isolated Rabbit Lungs. The American Review of Respiratory Disease, 1987, 136, 964-972.	2.9	54
720	Septic Lung. Clinical Infectious Diseases, 1987, 9, S570-S579.	5.8	25

#	Article	IF	CITATIONS
721	Release of leukotrienes into the perfusate of calcium-ionophore stimulated rabbit lungs. Biochemical Pharmacology, 1986, 35, 183-193.	4.4	54
722	Pseudomonas aeruginosa cytotoxin stimulates prostacyclin production in cultured pulmonary artery endothelial cells: Membrane attack and calcium influx. Journal of Cellular Physiology, 1985, 123, 64-72.	4.1	79
723	Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro. Lipids and Lipid Metabolism, 1985, 835, 58-67.	2.6	58
724	Calmodulin and the Lung Arachidonic Acid System. , 1985, , 401-421.		1
725	Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. Novartis Foundation Symposium, 0, , 196-213.	1.1	12
726	Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Frontiers in Immunology, $0,13,1$	4.8	7